Literature DB >> 17604717

AKT/PKB signaling: navigating downstream.

Brendan D Manning1, Lewis C Cantley.   

Abstract

The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Here, we review the molecular properties of Akt and the approaches used to characterize its true cellular targets. In addition, we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604717      PMCID: PMC2756685          DOI: 10.1016/j.cell.2007.06.009

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  114 in total

1.  Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein.

Authors:  Lorena Eguez; Adrian Lee; Jose A Chavez; Cristinel P Miinea; Susan Kane; Gustav E Lienhard; Timothy E McGraw
Journal:  Cell Metab       Date:  2005-10       Impact factor: 27.287

2.  Binding and phosphorylation of par-4 by akt is essential for cancer cell survival.

Authors:  Anindya Goswami; Ravshan Burikhanov; Aurelie de Thonel; Naoya Fujita; Mamta Goswami; Yanming Zhao; John E Eriksson; Takashi Tsuruo; Vivek M Rangnekar
Journal:  Mol Cell       Date:  2005-10-07       Impact factor: 17.970

Review 3.  Activation of AKT kinases in cancer: implications for therapeutic targeting.

Authors:  Alfonso Bellacosa; C Chandra Kumar; Antonio Di Cristofano; Joseph Robert Testa
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

4.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

Authors:  Anders Sundqvist; Maria T Bengoechea-Alonso; Xin Ye; Vasyl Lukiyanchuk; Jianping Jin; J Wade Harper; Johan Ericsson
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

5.  Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis.

Authors:  Eric Ackah; Jun Yu; Stefan Zoellner; Yasuko Iwakiri; Carsten Skurk; Rei Shibata; Noriyuki Ouchi; Rachael M Easton; Gennaro Galasso; Morris J Birnbaum; Kenneth Walsh; William C Sessa
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

7.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.

Authors:  Jiyong Liang; Judit Zubovitz; Teresa Petrocelli; Rouslan Kotchetkov; Michael K Connor; Kathy Han; Jin-Hwa Lee; Sandra Ciarallo; Charles Catzavelos; Richard Beniston; Edmee Franssen; Joyce M Slingerland
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

8.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

9.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

10.  The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes.

Authors:  Daniel C Berwick; Ingeborg Hers; Kate J Heesom; S Kelly Moule; Jeremy M Tavare
Journal:  J Biol Chem       Date:  2002-07-09       Impact factor: 5.157

View more
  2000 in total

1.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

3.  A novel missense mutation in the HECT domain of NEDD4L identified in a girl with periventricular nodular heterotopia, polymicrogyria and cleft palate.

Authors:  Koji Kato; Fuyuki Miya; Ikumi Hori; Daisuke Ieda; Kei Ohashi; Yutaka Negishi; Ayako Hattori; Nobuhiko Okamoto; Mitsuhiro Kato; Tatsuhiko Tsunoda; Mami Yamasaki; Yonehiro Kanemura; Kenjiro Kosaki; Shinji Saitoh
Journal:  J Hum Genet       Date:  2017-05-18       Impact factor: 3.172

4.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

5.  Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.

Authors:  Tao Ma; Xueliang Du; Joseph E Pick; Guangzhi Sui; Michael Brownlee; Eric Klann
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

6.  The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

Authors:  Simone Codeluppi; Camilla I Svensson; Michael P Hefferan; Fatima Valencia; Morgan D Silldorff; Masakatsu Oshiro; Martin Marsala; Elena B Pasquale
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

7.  EGFR signals to mTOR through PKC and independently of Akt in glioma.

Authors:  Qi-Wen Fan; Christine Cheng; Zachary A Knight; Daphne Haas-Kogan; David Stokoe; C David James; Frank McCormick; Kevan M Shokat; William A Weiss
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

8.  Delineating the signals by which repetitive deformation stimulates intestinal epithelial migration across fibronectin.

Authors:  Christopher P Gayer; Lakshmi S Chaturvedi; Shouye Wang; Brittany Alston; Thomas L Flanigan; Marc D Basson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

10.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.